PPA
VTGN icon

Parametric Portfolio Associates’s VistaGen Therapeutics VTGN Stock Holding History

Parametric Portfolio Associates’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$16K Sell
434
-831
-66% -$36.2K ﹤0.01% 3664
2021
Q4 		$74K Sell
1,265
-136
-10% -$8.85K ﹤0.01% 3578
2021
Q3 		$115K Buy
1,401
+999
+249% +$86.8K ﹤0.01% 3517
2021
Q2 		$38K Buy
+402
New +$29.8K ﹤0.01% 3546

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return

Parametric Portfolio Associates's VTGN Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its VistaGen Therapeutics (VTGN) stake by 66% in Q1 2022, selling an estimated $36.2K and leaving 434 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3664.

Parametric Portfolio Associates first reported a position in VTGN in Q2 2021 and has held it in 4 quarters since. The position peaked at $115K in Q3 2021. 116 funds tracked by Wall St. Rank hold VTGN as of Q1 2022.

  • Parametric Portfolio Associates held 434 shares of VistaGen Therapeutics worth $16K as of Q1 2022.
  • Parametric Portfolio Associates sold 831 VistaGen Therapeutics shares in Q1 2022, an estimated $36.2K.
  • VistaGen Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3664 holding.
  • Parametric Portfolio Associates first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's VistaGen Therapeutics position peaked at $115K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.